<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395080</url>
  </required_header>
  <id_info>
    <org_study_id>DEK-DKK1-P204</org_study_id>
    <nct_id>NCT03395080</nct_id>
  </id_info>
  <brief_title>A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma</brief_title>
  <acronym>P204</acronym>
  <official_title>A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leap Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leap Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in&#xD;
      Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer,&#xD;
      Epithelial Ovarian Cancer, or Carcinosarcoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study employs a &quot;basket&quot; design to concurrently investigate DKN-01 as monotherapy and in&#xD;
      combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC),&#xD;
      epithelial ovarian cancer (EOC), or carcinosarcoma (malignant mixed Mullerian tumor [MMMT].&#xD;
      Thus, 6 distinct patient groups are being independently investigated:&#xD;
&#xD;
        1. 300mg DKN-01 monotherapy in recurrent EEC (Group 1)&#xD;
&#xD;
        2. 300mg DKN-01+paclitaxel in recurrent EEC (Group 2)&#xD;
&#xD;
        3. 300mg DKN-01 monotherapy in recurrent EOC (Group 3)&#xD;
&#xD;
        4. 300mg DKN-01+paclitaxel in recurrent EOC (Group 4)&#xD;
&#xD;
        5. 600mg DKN-01 monotherapy in recurrent carcinosarcoma (MMMT) (Group 5)&#xD;
&#xD;
        6. 600mg DKN-01+paclitaxel in recurrent carcinosarcoma (MMMT) (Group 6)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in EEC or EEC patients.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities as evaluated by NCI CTCAE v5.0 of DKN-01 600 mg ± paclitaxel in patients with recurrent carcinosarcoma (MMMT) in Carcinosarcoma (MMMT) patients.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (C max) will be measured.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The time taken to reach the maximum plasma concentration (T max) will be measured.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curved (AUC) will be measured.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective disease control rate (ODCR) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities as evaluated by NCI CTCAE, version 4.03 as DKN-01 as monotherapy or in combination with paclitaxel in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response (DoCR) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTTF) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical benefit (DoCB) in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) in Carcinosarcoma (MMMT) patients.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-DKN-01 antibodies in human serum in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT)</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities to study treatment regimen in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT) as evaluated by NCI CTCAE v5.0.</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects with response to therapy in patients with and without activating β-catenin mutations and/or Wnt signaling genetic alterations in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT)</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dickkopf-1 (DKK1) concentration in serum and plasma relative to safety and efficacy outcomes in patients with recurrent EEC or EOC or Carcinosarcoma (MMMT).</measure>
    <time_frame>Baseline to study completion (approximately 6 months)</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>DKN-01 monotherapy in recurrent EEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DKN-01 monotherapy in recurrent EEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01+paclitaxel in recurrent EEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DKN-01+paclitaxel in recurrent EEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01 monotherapy in recurrent EOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DKN-01 monotherapy in recurrent EOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01+paclitaxel in recurrent EOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg DKN-01+paclitaxel in recurrent EOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01 monotherapy in carcinosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg DKN-01 monotherapy in carcinosarcoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01 +paclitaxel in carcinosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg DKN-01 +paclitaxel in carcinosarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>DKN-01 +paclitaxel in carcinosarcoma</arm_group_label>
    <arm_group_label>DKN-01+paclitaxel in recurrent EEC</arm_group_label>
    <arm_group_label>DKN-01+paclitaxel in recurrent EOC</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg DKN-01</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>DKN-01 monotherapy in recurrent EEC</arm_group_label>
    <arm_group_label>DKN-01 monotherapy in recurrent EOC</arm_group_label>
    <arm_group_label>DKN-01+paclitaxel in recurrent EEC</arm_group_label>
    <arm_group_label>DKN-01+paclitaxel in recurrent EOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600mg DKN-01</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>DKN-01 +paclitaxel in carcinosarcoma</arm_group_label>
    <arm_group_label>DKN-01 monotherapy in carcinosarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis:&#xD;
&#xD;
               1. Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either&#xD;
                  primary surgical specimen or biopsy for recurrence) of recurrent previously&#xD;
                  treated EEC.&#xD;
&#xD;
               2. Epithelial Ovarian Cancer: histologically confirmed diagnosis (by either primary&#xD;
                  surgical specimen or biopsy for recurrence) of recurrent&#xD;
                  platinum-resistant/refractory EOC, primary peritoneal, or fallopian tube cancer&#xD;
                  (i.e., disease recurrence within 6 months of completion of or progression during&#xD;
                  platinum-based chemotherapy).&#xD;
&#xD;
               3. Carcinosarcoma/Malignant Mixed Mullerian Tumors: histologically confirmed&#xD;
                  diagnosis (by either primary surgical specimen or biopsy for recurrence) of&#xD;
                  recurrent uterine or ovarian carcinosarcoma (MMMT). Patients must have had only 1&#xD;
                  prior chemotherapeutic regimen for management of carcinosarcoma that may have&#xD;
                  been included chemotherapy (including in adjuvant setting), chemotherapy and&#xD;
                  radiotherapy, and/or consolidation/maintenance therapy.&#xD;
&#xD;
          2. Refractory or intolerant to at least one prior standard therapy(ies) for metastatic or&#xD;
             locally advanced disease (see Inclusion Criterion #1c for Groups 5-6).&#xD;
&#xD;
               1. If prior therapy consisted of palliative chemoradiation therapy, it will be&#xD;
                  considered one line of therapy.&#xD;
&#xD;
               2. Prior treatment with paclitaxel as part of definitive therapy regimen is&#xD;
                  acceptable, provided the patient is not intolerant of paclitaxel.&#xD;
&#xD;
               3. Patients who are not eligible to receive paclitaxel will be allowed to receive&#xD;
                  single agent DKN-01.&#xD;
&#xD;
          3. Tumor tissue for mandatory pre-treatment and on-treatment biopsies.&#xD;
&#xD;
          4. One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.&#xD;
&#xD;
          5. Ambulatory and ≥18 years of age.&#xD;
&#xD;
          6. ECOG performance status (PS) of 0 or 1&#xD;
&#xD;
             a. ECOG PS of 2 may be eligible upon the review and approval of the Medical Monitor.&#xD;
&#xD;
          7. Estimated life expectancy of at least 3 months, in the judgment of the Investigator.&#xD;
&#xD;
          8. Disease-free of active second/secondary or prior malignancies for ≥2 years with the&#xD;
             exception of currently treated basal cell, squamous cell carcinoma of the skin, or&#xD;
             carcinoma in-situ of the cervix or breast.&#xD;
&#xD;
          9. Acceptable liver, renal, hematologic and coagulation function&#xD;
&#xD;
         10. Females of child bearing potential and male partners of female patients must agree to&#xD;
             use adequate contraception during the study and for 6 months after their last dose of&#xD;
             study drug.&#xD;
&#xD;
         11. Reliable and willing to make themselves available for the duration of the study and&#xD;
             are willing to follow study-specific procedures.&#xD;
&#xD;
         12. Provided written informed consent prior to any study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with the following pure histologies of endometrial or ovarian cancer are not&#xD;
             eligible for enrollment: germ cell, sex cord stroma, or sarcoma.&#xD;
&#xD;
          2. New York Heart Association Class III or IV cardiac disease, myocardial infarction&#xD;
             within the past 6 months, or unstable arrhythmia.&#xD;
&#xD;
          3. Fridericia-corrected QT interval (QTcF) &gt; 470 msec (female) or history of congenital&#xD;
             long QT syndrome.&#xD;
&#xD;
          4. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study&#xD;
             entry requiring systemic therapy.&#xD;
&#xD;
          5. Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface&#xD;
             antigen (HBSAg), or hepatitis C antibodies (HCAb), unless hepatitis C virus&#xD;
             ribonucleic acid (HCV RNA) undetected/negative.&#xD;
&#xD;
          6. History of major organ transplant (i.e., heart, lungs, liver, or kidney).&#xD;
&#xD;
          7. History of autologous/allogenic bone marrow transplant.&#xD;
&#xD;
          8. Serious nonmalignant disease&#xD;
&#xD;
          9. Pregnant or nursing.&#xD;
&#xD;
         10. History of osteonecrosis of the hip or have evidence of structural bone abnormalities&#xD;
             in the proximal femur on MRI scan that are symptomatic and clinically significant.&#xD;
&#xD;
         11. Symptomatic central nervous system (CNS) malignancy or metastasis.&#xD;
&#xD;
         12. Known osteoblastic bony metastasis&#xD;
&#xD;
         13. Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days&#xD;
             for nitrosoureas or mitomycin C)&#xD;
&#xD;
         14. Any hormonal therapy directed at the malignant tumor must be discontinued at least one&#xD;
             week prior to study entry.&#xD;
&#xD;
         15. Clinically significant peripheral neuropathy at the time of study entry. Patients with&#xD;
             pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01&#xD;
&#xD;
         16. History of hypersensitivity reactions to paclitaxel or other drugs formulated in&#xD;
             Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these&#xD;
             hypersensitivities will be eligible to receive single agent DKN-01&#xD;
&#xD;
         17. Prior radiation therapy within 14 days prior to study entry&#xD;
&#xD;
         18. Currently receiving any other investigational agent or received an investigational&#xD;
             agent within last 30 days of study entry.&#xD;
&#xD;
         19. Previously treated with an anti-DKK1 therapy&#xD;
&#xD;
         20. Significant allergy to a pharmaceutical therapy that, in the opinion of the&#xD;
             Investigator, poses an increased risk to the patient&#xD;
&#xD;
         21. Active substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Sirard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leap Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Arend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health System Clinical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center - University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epithelial histology</keyword>
  <keyword>Wnt pathway</keyword>
  <keyword>DKK1</keyword>
  <keyword>endometrial</keyword>
  <keyword>uterine</keyword>
  <keyword>ovarian</keyword>
  <keyword>carcinosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

